Toutes les études
Actif, mais pas en recrutementPHASE3INTERVENTIONNEL

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

This clinical trial is looking at how well and how safely a medication called Xeomin works to prevent very frequent (chronic) migraines. People taking part will get injections in their head and neck muscles, either Xeomin or a dummy injection (placebo). The main goal is to find out if Xeomin injections can lower the number of days people experience migraines each month. The study will last around a year, with a few visits to the clinic for treatments and check-ups, and some remote check-ins. If you have chronic migraines, this study aims to explore a potential new way to manage them.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE3
Sponsor
Merz Therapeutics GmbH
Objectif d'inscription
808
Démarrer
21 août 2025
Achèvement estimé
01 Sep 2027

De quoi parle cette étude ?

This study is a clinical trial exploring a new treatment option for people who experience chronic migraine. Chronic migraine means you have headaches very often – typically 15 or more days a month, with 8 or more of those being migraine days. It can be incredibly disruptive to daily life, and finding effective ways to manage it is really important.

The treatment being tested is called Xeomin. It's given as injections into the muscles of the head and neck. We want to see if these injections can help reduce how often people get migraines. To do this fairly, some participants will receive the actual Xeomin injections, while others will receive a 'placebo' – which looks exactly like Xeomin but doesn't contain any active medicine. This allows researchers to compare the effects of Xeomin against what would happen if people weren't getting the active drug.

The main aim of the study is to measure if people receiving Xeomin have fewer migraine days each month compared to those receiving the placebo. This kind of research is vital because it helps doctors and patients understand if a new treatment is safe and effective before it becomes widely available. We're hoping to find a new way to bring relief to those suffering from chronic migraine.

Points clés

  • Tests a new injection (Xeomin) for chronic migraine.
  • Compares Xeomin to a dummy injection (placebo).
  • Involves injections in head and neck muscles.
  • Study lasts about one year with in-person and remote visits.
  • Aims to reduce the number of migraine days.
  • Suitable for adults with long-term frequent migraines.

Qui peut être éligible ?

To join this study, you need to be an adult (18 years or older) and have been diagnosed with chronic migraine for at least a year. Your migraines should have started before you turned 50. For the three months before the study starts, and during the final month of screening, you should have had at least 15 headache days per month, with at least 8 of those being migraine days.

There are also some reasons why you might not be able to join. For example, if you have other specific types of headache diagnoses (apart from common tension headaches or medication overuse headaches), or if you're currently taking more than one medication specifically to prevent migraines. Also, if you've recently stopped a certain type of migraine prevention medication (called anti-CGRP/anti-CGRP receptor treatment) within the last five months, you wouldn't be eligible.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Have you been diagnosed with chronic migraine for at least a year?
  3. Did your migraines start before you turned 50?
  4. Do you currently have headaches on at least 15 days a month, with at least 8 of those being migraines?
  5. Are you *not* currently taking more than one prescribed medication specifically to prevent migraines?
  6. Have you *not* stopped CGRP migraine prevention treatment within the last 5 months?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, the study will last about 52 to 55 weeks, which is roughly one year. It starts with a ‘screening’ period of 4 to 5 weeks to make sure the study is a good fit for you.

During the study, you'll receive four sets of injections. Each set of injections will be given about 12 weeks (3 months) apart. You'll have 14 visits in total over the year. The first and last visits, along with the four treatment visits where you get your injections, will be in person at the study clinic. The other 8 check-ups will be done remotely, meaning you can do them from home over the phone or by video call. You'll also be asked to keep a headache diary to track your migraines.

Risques et avantages potentiels

Taking part in a clinical trial offers the chance to access a new treatment that isn't yet widely available, and you'll be closely monitored by medical professionals. However, there's no guarantee the treatment will work for you, and there might be side effects from the injections or other aspects of the study. The injections involve needles, which can cause discomfort or bruising. You might also experience side effects like muscle weakness or headaches, though we don't know the full range yet for Xeomin in this setting. You can withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (111)

  • TrialSphere Corp, Merz Investigational Site #0010513
    Code postal vérifié
    Chandler, United States
  • Arizona Neuroscience Research, Merz Investigational Site #0010521
    Code postal vérifié
    Phoenix, États-Unis
  • Baptist Health Medical Center, Merz Investigational Site #0010520
    Code postal vérifié
    Little Rock, États-Unis
  • Chemidox Clinical Trials Inc, Merz Investigational Site #0010488
    Code postal vérifié
    Lancaster, États-Unis
  • Clinical Research Institute, Merz Investigational Site #0010487
    Code postal vérifié
    Los Angeles, États-Unis
  • BNL Health, Merz Investigational Site #0010501
    Code postal vérifié
    Los Angeles, États-Unis
  • Clinical Trials Management Services, Merz Investigational Site #0010526
    Code postal vérifié
    Thousand Oaks, United States
  • Hasbani Neurology, Merz Investigational Site #0010509
    Code postal vérifié
    New Haven, États-Unis
  • Yale Center for Clinical Investigations, Merz Investigational Site #0010527
    Code postal vérifié
    New Haven, États-Unis
  • New England Institute Neurology and Headache, Merz Investigational Site #0010441
    Code postal vérifié
    Stamford, États-Unis
  • Northwest Florida Clinical Research Group, Merz Investigational Site #0010286
    Code postal vérifié
    Gulf Breeze, United States
  • Nexus Clinical Research Center, Merz Investigational Site #0010514
    Code postal vérifié
    Homestead, United States

Questions fréquentes

What is chronic migraine?

Chronic migraine means you experience headaches on 15 or more days per month, with at least 8 of those days being migraines, over a period of three months or more.

What is 'placebo'?

A placebo is a dummy treatment that looks exactly like the real medicine but contains no active drug. It helps researchers fairly compare the new treatment's effects.

Will I know if I'm getting Xeomin or the placebo?

No, during the study, neither you nor the study team will know whether you are receiving Xeomin or the placebo. This helps keep the study fair.

How long does each treatment last?

You will receive four treatments in total, with each set of injections given approximately 12 weeks (3 months) apart.

Puis-je arrêter de participer à l'étude si je change d'avis ?

Yes, you are free to stop participating in the study at any time, for any reason, without it affecting your future medical care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.